Introduction
The abnormal assembly of proteins is implicated in over 30 human disorders, which include Alzheimer's disease (Aβ ), Parkinson's disease (α-synuclein), and dialysis related amyloidosis (β2-microglobulin). [1] [2] [3] [4] Alzheimer's disease (AD) is perhaps best characterized by the extracellular deposits of the 39-42 amino acid amyloid-β peptides (Aβ) along with neurofibrillary tangles in the brains of patients. Aβ peptides arise from cleavage of the extracellular portion of the transmembrane amyloid-precursor protein (APP) by β-and γ-secretases. [5] [6] [7] The elucidation of the genetic, biochemical, and biophysical origins of Alzheimer's disease (AD) remains a complex and formidable challenge. The toxicity of processed Aβ peptide may include a combination of apoptosis, 8 disrupted Ca 2+ homeostasis, 9 toxic radicals, 10, 11 and complement formation. 12 Over the past decade Selkoe, 13 Lansbury, 14 Teplow, 15 Kelly, 4 Dobson, 16, 17 and Prusiner, 18 among many others have helped establish a general nucleation dependent paradigm for fibril formation ( Figure 1 ). These ongoing experiments have also demonstrated that the rate of fibrillization and the morphology of the final fibrillar state are strongly influenced by environmental factors (pH, salt, temperature, agitation, etc.); chemicals (proteins, lipids, cholesterol, metals, etc.); and by the nature of the seeding agent. 14 In the case of Aβ, evidence from both in vitro 19, 20 and in vivo 21, 22 studies strongly suggest that soluble oligomeric Aβ forms with β-sheet secondary structure are responsible for neurological toxicity ( Figure 1 ). 22, 23 In this review we will briefly present current structural paradigms in AD followed by a discussion of the molecular approaches towards targeting oligomers and fibrils.
The presence of amyloid plaque in the postmortem brains of patients suffering from Alzheimer's disease led to the hypothesis that these extracellular plaques were pathological to the neuronal cells. This view was further confirmed by in vitro experiments where Aβ fibrils upon incubation with rat hippocampal cultures were found to be toxic to these neuronal cells. [24] [25] [26] However, much current work with amyloidogenic proteins has led to a paradigm shift towards an oligomeric toxic species. The evidence for a toxic oligomeric intermediate rests on the following experiments: firstly, there seems to be a stronger correlation between "soluble Aβ" (monomer and oligomers of Aβ) in the brain and early cognitive dysfunction than there is between the Aβ deposits and clinical severity of AD; [27] [28] [29] [30] secondly, transgenic mice that overexpress APP exhibited neuronal and behavioral abnormalities before amyloid plaques were detected 31, 32 and thirdly, soluble oligomers of Aβ were found to be toxic to cell cultures 33, 34 and affected hippocampal long term potentiation when injected in transgenic mice. 21 , 35 Haass & Selkoe have also argued that Aβ aggregates present less surface area for interaction with the neurons as compared to the soluble intermediates which can easily diffuse into synaptic clefts and hence are better candidates for causing neuronal dysfunction. 36 Several of these intermediates have been validated in aggregation studies of purified Aβ, whereas some have also been isolated and purified from cell cultures and brains of transgenic mice (Table 1) .
Interestingly, studies in the similar Huntington's Disease, showed significantly less cell death when fibrils of polyglutamine oligomers of the huntingtin protein were present. 37, 38 This has led many researchers to postulate that in some cases the fibrillar aggregates may protect normal cells against toxic oligomeric intermediates. 39, 40 However, deposits of Aβ in AD brain do show surrounding dystrophic neuritis indicating that insoluble aggregates may be contributing to neuronal injury. 41 It is also possible that the large aggregates are in slow equilibrium with surrounding soluble oligomers which may be the actual toxic species (Figure 1) . Although, it is not clear that oligomers lie in the same pathway as fibrils as small molecules which inhibit oligomer formation but not fibril formation have been described. 42 Hence at the current time the true culprit in these diseases, whether fibrillar or oligomeric, remains to be unequivocally established. Studies on model protein aggregates are also aiding in this effort. 16, [43] [44] [45] [46] [47] Many experiments are underway to provide a molecular level understanding of the Aβ oligomers and the data are summarized in Table 1 . This data clearly suggests that even the actual dimensions of these oligomers, whether 2 nm, 20 nm, or even micellar, still remains to be established. The data presently suggest that it is very likely that multiple oligomeric species are implicated in the fibrillization pathway.
In comparison to our understanding of the oligomers, ongoing solid state NMR studies from Tycko are rapidly unraveling a true molecular description of the Aβ 1-40 fibrils. Current work suggests that the amyloid structure favors a C 2z symmetry 48 that is primarily stabilized by hydrophobic interactions involving L17, F19, A21, A30, I32, L34, and V36 at the "internal quaternary interface" (interface between β-sheets within a single layer of Aβ molecules) and I31, M35, and V39 at the "external quaternary interface" (interface between β-sheets of two separate layers of Aβ molecules) ( Figure 2 ). 49 Salt bridges formed between K28 and D23 also appear to be important for stability, as a lactam crosslink between K28 and D23 has been shown to delay fibrillization. 50 Once formed, the fibril structure may exclude water as significant changes in structure were not observed when water was removed by freeze-drying. In contrast to some earlier models, Tycko has proposed that native amyloid fibrils are more commonly composed of parallel β-sheets whereas the antiparallel arrangement may be predominant in fibrils formed from short peptides. 49 Emerging models of polyglutamine fibrils may also illuminate this issue. 51 Further biophysical characterization of these intermediates will allow for a structure guided discussion of how different known ligands interact with Aβ and provide a rational template for either stabilizing or disrupting these oligomers. It is perhaps possible that the ligands that target specific oligomers of Aβ will provide a method for trapping these intermediates for structural elucidation. The following discussion will entail a review of amyloid (oligomeric or fibrillar) binding molecules and new molecular approaches for preventing Aβ aggregation and toxicity, which has been the focus of most studies to date. Our review is divided into the following five sections: 1) Natu- Figure 1 . Model for the fibrillogenesis pathway for Aβ. 13 ral protein ligands that interact with Aβ, 2) Inhibition with modified peptides and peptidomimetics derived from the parent Aβ Sequence, 3) Targeting Aβ with antibodies, 4) Targeting amyloid with in vitro selected peptides and proteins, and 5) Targeting Aβ with small molecules.
Natural Protein Ligands that Interact with Aβ
Though the mechanism of toxicity of Aβ in the cellular environment is still not clearly understood, numerous experiments have been conducted to determine possible natural protein binding partners of Aβ. Some of these natural ligands may be a missing link between Aβ accumulation and cellular toxicity (Table 2) . A few of these interacting proteins which have been studied in greater detail are discussed below.
The conventional yeast two-hybrid system, used to detect protein-protein interactions in vivo, has been applied to Aβ. 57 This system was able to specifically report on the interaction of Aβ monomers in the yeast nucleus. A control bait protein which contained double Phe to Thr substitutions, at residues 19 and 20 of the hydrophobic core, did not produce appreciable signal, indicating that the observed Aβ interactions were likely specific.
Subsequently a similar yeast two-hybrid system was also used to identify an endoplasmic-reticulum associated binding protein (ERAB) from human brain and HeLa cell cDNA libraries. 58 ERAB was shown to co-precipitate with Aβ and suppression of ERAB activity led to a decrease in cellular toxicity of Aβ. This protein was identified as an alcohol dehydrogenase and was later termed Aβ-binding alcohol dehydrogenase or ABAD. A crystal structure of Aβ-bound ABAD has been solved. 59 This crystal structure shows that the active site is severely perturbed such that NAD binding is prevented. An ABAD derived peptide was shown to suppress Aβ toxicity while the overexpression of ABAD in the presence of Aβ led to an increase in oxidative stress in transgenic mice. An ELISA based screen has identified small molecule inhibitors of the Aβ-ABAD interaction. 60 The most potent of these inhibitors had an IC 50 value of <10 μM but its ability to decrease the cytotoxicity of Aβ remains to be demonstrated.
The early observations of increased phosphorylation of proteins in Alzheimer's patients led to the hypothesis that Aβ may directly perturb the activities of certain kinases. Indeed, the ac- tivities of purified casein kinase I and II (CKI and II) have been shown to be increased in a concentration dependent manner by Aβ when monitoring phosphorylation of casein. 61 Overexpression of a constituently active form of CKI has been shown to increase the amount of Aβ in brain tissue cultures. 86 Three different CKI-specific inhibitors were shown to decrease the amount of Aβ produced. This approach has the potential for identifying novel therapeutics for the treatment of Alzheimer's if the CKI/Aβ interaction correlates with cognitive failure. It is still to be established whether the observed effects are directly or indirectly mediated by Aβ in a physiological context. The activity-dependent neuroprotective protein (ADNP) was discovered by screening cDNA libraries by antibody maturation. A very short eight amino-acid segment of this protein, NAPVSIPQ, was shown to protect neuronal cells against Aβ at femtomolar concentrations. 63, 87 A study has shown that intranasal administration of this peptide can significantly reduce the levels of Aβ in transgenic mice model of Alzheimer's. 9 Again it is very possible that this peptide does not function by direct interaction with Aβ.
Transthyretin, a protein in the cerebral fluid, was found to bind to Aβ through fractionation of an Aβ-binding activity. 85 Subsequently, transgenic mice containing a mutation in the APP gene predisposing them to early onset AD, the Swiss mutation, were found to overexpress transthyretin. 88 This overexpression correlated with a decrease in the progression of AD The protofilament is a fourlayered β-sheet structure with C 2 symmetry about its long axis. Double-headed arrows indicate side chain-side chain and side chain-backbone contacts established by 2D 13 C-13 C NMR measurements or 15 N-13 C dipole-dipole couplings. b) Average structure resulting from ten independent molecular dynamics/energy minimizations runs on a cluster of twelve peptides, with interatomic distance and backbone torsion angle restraints dictated by solid-state NMR data. The four-layered β-sheet structure is stabilized primarily by hydrophobic interactions in the core of the protofilament. Polar and charged side-chains are on the exterior, with the exception of oppositely charged K28 and D23 side-chains, which form salt bridges. c) and d) Cartoon representations with residues 12-21 and 30-40 shaded. (Reprinted with permission from Cambridge University Press) symptoms such that disease onset was delayed. Forty-seven individual point mutants of transthyretin have been analyzed for Aβ-binding and inhibition of fibril formation. 89 All but two mutants, G42 and P55, bound Aβ, localizing the Aβ-binding activity to this region. Studies suggest that transthyretin decreases the rate of fibril formation by decreasing the lateral association of fibrils as well as decreasing the rate of elongation of fibrils. 90 These data would indicate that, at concentrations of 2 μM transthyretin and 140 μM Aβ, transthyretin binds to the fibrillar form of Aβ arresting the formation of plaques. This study is quite interesting, given that transthyretin itself is directly implicated in a different misfolding disease and one of the few instances where small molecules are known to inhibit aggregation by stabilizing the native state. 91 From the above studies with possible natural protein ligands of Aβ, it is clear that there are many possible candidate proteins that directly or indirectly interact with Aβ and modulate its activity. With a growing list of candidate proteins the physiological role of Aβ will likely be established, resulting in new methods for diagnosing and possibly treating AD. Structural details of true and potent Aβ bound complexes will likely provide the necessary molecular templates for the design of useful diagnostics and therapeutics as has been realized for transthyretin.
Inhibition with Modified Peptides and Peptidomimetics Derived from the Parent Aβ Sequence
Several elegant strategies have been used to rationally design peptidic inhibitors of Aβ aggregation, some of which are discussed in detail (Table 3 ). Many of these approaches rely on using fragments of the parent Aβ sequence as recognition elements in a dominant negative fashion. Typically, fibril disrupting chemical elements are incorporated into Aβ derived peptides in the form of N-or C-terminal modifications, conformationally constrained amino acids, or modifications to the peptide backbone. These concepts have also been applied to D-amino acid variants of the parent Aβ sequence. These different molecular design strategies are discussed below.
N-and C-terminal modifications
Inhibitors of fibril formation based on the hydrophobic region of Aβ are the most prevalent. Initial work in this area identified the KLVFF motif 92 as capable of inhibiting fibril formation. A variant of this core domain (Table 3 a) containing a polycationic disrupting region appended to the C terminus, KLVFFKKKKKK, was shown to increase the rate of fibril formation and cell viability. 93 , 94 The rate of fibril forma- tion increased with the number of lysine residues as follows: KLVFFKK<KLVFFKKKK<KLVFFKKKKKK. The effect of charge distribution and the orientation of the disrupting element was also verified using KLVFFEEEKKK and KKKKLVFF. Both of these peptides bound with less affinity to Aβ as determined by SPR. The ability of these peptides to accelerate fibril formation while decreasing toxicity is very intriguing, and suggests that the new fibrils are not toxic or that they are no longer in equilibrium with the toxic oligomeric intermediates. A peptide corresponding to Aβ 31-34 when appended to a N-terminal propionyl group ( Pr IIGL) 95 was shown to form fibers and was toxic to neuroblastoma cells. However, replacement of the propionyl group with an arginine (RIIGL) resulted in a peptide which inhibited fibril formation and reduced toxicity of Aβ, possibly sequestering the toxic oligomeric species and preventing interactions at the cell membrane. The above studies are quite significant as they suggest multiple new routes to interfere with Aβ assembly and may also be starting points for designing reagents that trap and stabilize intermediates that can be further studied at the molecular level.
Conformationally constrained peptides
Building on the observation that the hydrophobic core of Aβ was capable of inhibiting fibril formation, a conformationally constrained β-sheet breaker peptide has been designed. 96 The peptide, iAβ5, contains a single proline residue in the hydrophobic recognition sequence which is thought to disrupt fibril formation through unfavorable steric interactions or alternatively by redirecting Aβ assembly in alternate nontoxic arrangements. This peptide was reported to disassemble fibrils in vitro and to increase cell viability.
A new class of conformationally constrained peptides which contained α,α-disubstituted amino acids (Table 3 b) have been synthesized. 97 These α,α-disubstituted amino acids were incorporated in such a way that one face of the peptide would be sterically blocked. The peptide AMY-1 was shown to abrogate fibril formation for up to 4.5 months, whereas AMY-2 was shown to produce nonfibrillar aggregates. The authors suggest that this difference in activity may be attributed to the positioning of the hydrophilic tails in each peptide, such that the polyly- sine tail at the C terminus disrupts amyloid aggregation by interfering with committed assembly steps within the N-terminal hydrophobic region. Another interesting approach in this area of Aβ mimetics is the substitution of alternating amide hydrogens with methyl groups (Table 3 c ). This approach in principle serves to cap oligomeric domains and prevent the β-sheet propagation necessary for Aβ fibrillization. Furthermore, these N-methylated peptides tend to have increased solubility (by preventing self aggregation), increased resistance to proteolytic degradation, and the possibility for increased blood-brain barrier penetration. Meredith and co-workers designed inhibitors based on the much studied hydrophobic core Aβ motif KLVFFAE, containing N-methylated amino acids. 98 These peptides were found to inhibit fibril formation and disassemble preformed fibrils in vitro. The most potent inhibitor contained alternating sites of Nmethylation, Aβ16-22m. N-methylated Aβ derived peptides have also been reported by Doig based on Aβ 25-35 (GSNK-GAIIGLM). 99 The authors showed that NMeGly 25 had no activity and actually showed similar aggregation and toxicity levels as that of the wild-type sequence. However, NMeGly 33 was shown to completely inhibit fibril formation, disassemble preformed fibrils, and reduce cellular toxicity. These results would imply that the position of N-methylation is crucial for efficacy and likely maps to a critical region of the growing amyloid fibril (Table 3) . Meredith and co-workers have also investigated the effect of replacing the amide backbone with ester bond surrogates at alternating positions. 100 The peptide, Aβ16-20e, was synthesized and shown to inhibit fibril formation and disassemble fibrils in vitro. This ester containing peptide likely functions by preventing hydrogen-bond propagation as seen in the alternating N-methylation approach. What is also very interesting is the reported disassembly of pre-existing fibers, which may suggest that many of these peptides can bind at the end of the fibrils and possibly serve to influence the thermodynamic equilibrium between oligomers and fibrils.
D-Amino acid peptides
Doig and coworkers systematically explored the structure-activity relationship of numerous peptides based on the KLVFFA sequence. 102 The initial library of KLVFFA peptides revealed that peptides containing the core LVFFL motif were the most effective at inhibiting fibrillization. Efficacy was increased when peptides were constructed entirely from D-amino acids and singly methylated at the first and fifth positions or doubly methylated at both positions. Using this information the authors developed four new libraries to ascertain the effects of the position of N-methylation and amino acid preference. The authors found that large branched hydrophobic side chains were preferred at positions 1-4 and that a single N-methylated site was sufficient for fibril inhibition. All peptides from this final compound library were shown to decrease toxicity in PC12 cells using the MTT assay. The most potent compound, SEN 304, was determined to be more active than the β-sheet breaker peptide 96 as determined by ThT and MTT assays.
Other interesting approaches 105 have targeted Aβ utilizing peptides based on the GxFxGxF scaffold expected to interact with the C terminus of Aβ. The most active compound RGTWEGKW was shown to inhibit fibril formation and reduce cellular toxicity. The authors propose that alternating hydrophilic-hydrophobic nature of this peptide may help to disrupt Aβ aggregation. A different approach has utilized the so-called surface tension-modifying peptides 106 that actually increased the rate of Aβ fibril formation several-fold. It remains to be seen if such peptides prevent the build up of the toxic soluble intermediates by sequestering Aβ in the fibril state.
Thus, it is clear that the considerable efforts in the rational design of Aβ-targeting molecules based on the parent Aβ sequence have been quite fruitful in providing a large class of compounds with different modes of activity. 107 These peptidomimetic molecules by themselves or with further modifications provide a class of reagents that may help elucidate the mechanism of amyloid aggregation, perhaps by trapping intermediates, as well as providing inroads into the design of diagnostic and therapeutic reagents.
Targeting Aβ with Antibodies
Antibodies, because of their specificity and conformation dependence, have been attractive choices for potential therapeutic strategies for the treatment of AD. They are now also being used to distinguish between fibrils and prefibrillar intermediates in the aggregation pathway. The recent developments in Aβ immunotherapy and in the use of site-directed antibodies as tools for understanding the amyloid aggregation pathway is elaborated in the following two subsections:
Aβ Immunotherapy
Antibodies generated against Aβ 1-42 were shown to lower cerebral amyloid plaques in mouse models. 108 However, a clinical trial using Aβ 1-42 fibrils for active immunization was halted when ~6 % of the patients developed meningoencephalitis, 109, 110 possibly due to a potent T-cell mediated immune response. To avoid the risk of such an adverse autoimmune response and to develop safer vaccines, newer strategies are being tested in Aβ immunotherapy using the N terminus Aβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] fragment which has been demonstrated to lack T-cell reactivity in mice and humans. 111, 112 As a monovalent linear peptide would not be an effective immunogen, Agadjanyan et al. synthesized the Aβ 1-15 fragment in tandem with an HLA DR binding peptide (PADRE). 113 PADRE is a 13-residue nonnatural peptide that is a potent T-cell epitope. PADRE-Aβ 1-15 was synthesized on a multiple antigenic peptide (MAP) platform to enhance the immune response by a multivalent effect. Antibodies induced by PADRE-Aβ 1-15 -MAP were specific to Aβ and did not bind to the MAP backbone or PADRE. These antibodies prevented Aβ fibrillization and the splenocytes from mice showed T-cell stimulation only to PADRE and not to Aβ T-cell epitopes. In a similar approach, bacterial thioredoxin (Trx) was used as a scaffold to link four repeats of Aβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . 114 The anti-Trx (Aβ15) 4 antibody generated against this epitope bound to Aβ 1-42 fibrils and oligomers but not monomers and reduced Aβ pathology in transgenic AD mice.
In a complementary approach, Maier et al. have tested peptide immunogens consisting of tandem repeats of di-lysine linked Aβ 1-15 sequences (Aβ 1-15 -KK-Aβ 1-15 ) and found them to be more effective in boosting the immune response as com-pared to Aβ 1-15 itself. 42 Of these, Aβ 1-15 -KK-Aβ 1-15 and RGD-Aβ 1-15 -KK-Aβ 1-15 significantly reduced Aβ plaque load in transgenic AD mice without splenocyte proliferation. 115 Animals immunized with Aβ 1-15 -KK-Aβ 1-15 also showed improved acquisition of memory as compared to the controls. Thus, these new studies using active immunization show much promise but will ultimately have to demonstrate safety and efficacy in clinical trials. It would also be interesting to pursue the in vitro study of the individual antibodies elicited by these active immunization regimes and clearly establish the molecular mechanism for their interactions with Aβ.
Antibodies as probes of Aβ intermediates
Antibodies are also emerging as useful chemical probes for delineating the steps in Aβ assembly. As mentioned earlier, many reports suggest the soluble oligomers and not the fibrils are the toxic species, 13 thus the interaction of specific antibodies with Aβ are being used to directly probe such intermediate species for a better understanding of the aggregation pathway. O'Nuallain and Wetzel described the generation of two conformation-specific antibodies, WO1 and WO2 that bound to Aβ 1-40 fibrils but not soluble Aβ species, even in the presence of a large excess of Aβ 1-40 monomers. 116 These antibodies were also able to bind amyloid fibrils of other proteins, which again strongly suggests that the final fibrillar form of Aβ is common to numerous proteins that form fibers. To generate polyclonal antibodies against the so-called Aβ-derived diffusible ligands (ADDLs), the toxic soluble oligomers of Aβ 1-42 , Lambert et al. incubated Aβ solution for 48 h at 4 °C, centrifuged at 14 000 g for 10 min, and used the supernatant (0.24 mg Aβ mL −1 ) as an immunogen. 117 This supernatant (defined as ADDL preparation) was free of amyloid fibrils and contained a mixed population of spherical oligomers and monomers of Aβ (as observed by AFM). The antibodies produced recognized trimers, tetramers, and surprisingly also fibrils of Aβ 1-42 in dot-blot assays. At higher concentrations the antibody was also found to bind monomers. A more specific antibody probe against such oligomers was prepared in a controlled fashion by Kayed et al. 118 They reacted gold nanoparticles with a C-terminal thioester containing Aβ 1-40 to synthesize micellar mimetics of Aβ oligomers (Figure 3 ). These micellar mimetics were similar in size when compared to the soluble intermediates and were used to immunize rabbits. The anti-oligomer antibody generated did not react with monomers or fibrils of Aβ 1-40 , but was reported to exclusively precipitate Aβ 1-40 oligomers in dot-blot assays. The smallest oligomeric species recognized by this antibody had an apparent molecular weight of 40 kDa on size exclusion chromatography, which corresponds to an octamer of Aβ . The anti-oligomer antibody is now commercially available from Invitrogen and is being utilized to delineate the mechanism of small molecules that influence Aβ oligomerization, which is discussed in Section 5 of this review. 42 Again, it is surprising that this new anti-oligomer antibody also recognized soluble intermediates of other amyloidogenic proteins and peptides. These results in conjunction with the Aβ fibril targeting antibody suggest that not only are the final fibrillar structures similar for different proteins but so are many of the intermediates.
Targeting Amyloid with in vitro Selected Peptides and Proteins
Though antibodies are clearly the first established choice for targeting proteins and peptides, phage displayed peptides and protein scaffolds have also emerged as an alternate route for targeting Aβ. 119, 120 Phage display approaches generally enrich for an immobilized protein of interest and a complicated immunization protocol is not necessary. Results in this area are tabulated (Table 4 ) and discussed in this section.
In one of the earliest studies in this area, a library of 20 residue peptides was used to select for Aβ 1-40 binding using phage display. 121 Only two peptides were identified from this selection and were shown to be capable of staining Aβ deposits. The sequences suggested an aromatic rich motif: (W/F) X 5 (W/F)X 2/3 (W/F) which sometimes contained proline residues suggesting a turn conformation.
Mirror-image phage display allowing for the eventual identification of D-amino acid peptides (Figure 4 ) has been utilized for the discovery of peptides which bind Aβ. 125 In this strategy a synthetic D-amino acid version (enantiomer) of the target is immobilized, against which a library containing L-amino acid peptides is selected. Once L-amino acid binders are identified, their D-enantiomers are synthesized and interrogated for binding to the L-amino acid target. This is an elegant approach for the development of peptide inhibitors that are resistant to proteolytic cleavage. Using this approach Wiesehen and co-workers immobilized the full length D-enantiomer of Aβ 1-42 and selected binders from a phage-displayed peptide library. 122 The D-enantiomer of the most prevalent sequence from this selection, D-QSHYRHISPAQV, binds the natural L-enantiomer of Aβ (1-42) with an apparent dissociation constant of 400 nM, though the stoichiometry of the complex remains to be explored in detail. Appropriately labeled analogues of this peptide were also shown to be effective in staining Aβ deposits in brain tissues. However, the effect of this peptide on Aβ aggregation has not been determined to date.
Phage display using the KLVFF core motif was used to identify peptides which bound different species in the Aβ aggregation pathway. 123 Two libraries were used to assess the effect of polar residues on binding and the sequence requirements of the core motif. Both libraries were screened against aggregated and monomeric Aβ. Surprisingly, peptides selected for binding to the monomeric species did not effect the aggregation rate whereas those selected for binding to the aggregated species did. The ability of these peptides to promote aggregation correlated with their relative affinities for the N terminus of Aβ. The observation that peptides can be selected to bind specifically to different intermediates in the Aβ aggregation pathway opens up the possibility of producing tractable reagents for deciphering amyloid aggregation kinetics and thermodynamics.
We have recently utilized phage display to isolate variants of a small β-sheet scaffold 126 that likely binds to intermediates in the aggregation pathway of Aβ. 124 In this selection scheme ( Figure 5 ) a phage-displayed library containing eight randomized residues on the first two β-strands of the small IgG binding protein, HTB1, was generated. This library was first enriched for proteins that maintain the parent fold by IgG selection and subsequently selected against Aβ 1-40 ( Figure 5 ). Several proteins were isolated, notably one of these small β-sheet rich proteins, TJ10, maintained its structure and was shown to inhibit Aβ 1-40 aggregation in a stoichiometric manner. Initial dynamic light scattering experiments suggest that TJ10 interacts and likely traps soluble oligomers of Aβ 1-40 that range from 10-300 nm in diameter. This approach has the potential for providing a structural handle on an Aβ 1-40 binding protein motif not easily realizable with smaller unstructured peptides. The results from this selection also correlate well with the previously described selections with both antibodies and peptides, where aromatic residue rich sequences are strongly favored. From a molecular perspective this may suggest a possible common binding mode for Aβ where aromatic residues in suitable protein and peptide scaffolds interdigitate with an existing core Aβ structure. In many of the above cases, experiments need to be performed to explore whether these Aβ selected peptides and proteins also target multiple amyloidogenic proteins as observed in the case of the previously described antibodies.
Targeting Aβ with Small Molecules
In the past decade numerous organic compounds have been studied for the inhibition of amyloid aggregation as a direct therapeutic strategy for the treatment of amyloidosis. These include surfactants, 127 Cu/Zn chelators, 128 known bioactive molecules (for example, apomorphine, 129 rifamycine, 130 curcumin, 131 porphyrins, 130 ), and sulfonated dyes such as Congo red and its derivatives. 132 In fact, Congo red was the first small molecule reported to bind to amyloid in tissue sections and exhibited the characteristic yellow-green birefringence under cross polarizers. 133, 134 Later thioflavin T (ThT) and S (ThS) were also shown to characteristically stain amyloid deposits. 135, 136 These two dyes are the classic reagents for determining characteristic β-sheet mediated fibrillization seen for all amyloid forming proteins. It speaks to the difficulty in the biophysical studies in this arena that the mode of interaction of these dyes with amyloid aggregates is still not clearly understood, though solid-state NMR studies may soon establish a molecular description of these interactions. Many reports indicate that these dyes selectively interdigitate between amyloid strands and it was believed that these dyes exclusively bind fibrils with β-sheet conformation. However, a report showed that Congo red could also form complexes with proteins having α, α/β and β conformations. 137 Analogous studies with ThT, the reagent of choice for following Aβ aggregation, need to be carried out as many reports on Aβ inhibition are based on these assays. Congo red and ThT have also been shown to inhibit fibril formation 42, 138 at higher concentrations. Thus chemical derivatives of these dyes, with enhanced permeability through the blood-brain barrier, have been synthesized (Table 5 ) as in vivo imaging probes. [139] [140] [141] Results from these ongoing studies may help in early diagnosis of AD. Table 5 . Chemical derivatives of Congo red and ThT used as imaging probes for detecting amyloid plaque.
Fluorogenic and radiolabeled derivatives of Congo red and ThT * represents the atom radiolabeled.
Not surprisingly perhaps, many reported small molecule inhibitors are similar to Congo Red and ThT, in that they are planar and aromatic. The possible mode of interaction with Aβ has been reviewed by Porat et al. 142 It is also interesting to again note that many of the proteins and peptides selected to bind Aβ also contain a preponderance of aromatic residues. It is tempting to speculate that both small molecules and aromatic amino acid residues can intercalate within grooves created by β-sheets in both the soluble oligomeric forms as well as the large fibrils.
Many studies with small molecules have focused on the inhibition of fibril formation, however Blanchard et al. have screened a library of >3000 small molecules in an attempt to discover compounds that reduce the β-sheet content of preformed fibrils of Aβ 42 . 143 Of the six lead compounds, 4,5-dianilinophthalimide (DAPH) was reported to effectively reduce Aβ 1-42 fibrils when incubated with preformed Aβ 1-42 fibrils in equimolar amounts for 24 h. However, as is common to this field, the authors utilized the standard ThT assay in their screens, where there is the possibility of unintentionally isolating small molecules that interfere with ThT binding rather than disaggregate preformed amyloid fibers. Experiments have shown that many compounds (for example, melatonin, β-cyclodextrin, phthalocyanine, dimethyl yellow, and fenofibrate) competitively prevent the binding of ThT to the fibrils giving a possible false positive with regard to inhibition of Aβ aggregation. 42 However, elegant work by Lockhart et al. has shown that Congo red-type molecules do not share the same binding site as ThT on fibrils. 146, 147 Competition studies to determine the binding preferences of small molecule inhibitors and these classic ligands should be performed before conclusions regarding mechanisms of action are drawn.
With mounting evidence implicating soluble oligomeric intermediates as the toxic species, it is perhaps not sufficient to identify small molecule drug candidates that inhibit fibrillization but rather those that prevent toxicity. This is perhaps best exemplified by a study where naphthalene sulfonates were shown to inhibit fibril formation but stabilized the toxic oligomers. 148 In another example, the hydroxyaniline derivatives, RS-0406 (reported to inhibit aggregation) 149 and RS-0466 (reported to have no effect on aggregation) 145 (Table 6) were shown to inhibit the formation of SDS-stable Aβ oligomers in living cells. 144 The most comprehensive effort in this area is a recent report by Glabe and co-workers, 42 where they systematically evaluated 40 previously reported small molecule Aβ inhibitors. This study attempts to clarify the role of the small molecule inhibitors in terms of their ability to interact with Aβ oligomers or fibrils or both. A battery of assays were utilized, that included ThT fluorescence, turbidimetry, dot-blot/western blot assays with oligomer specific antibodies (A11), and TEM to understand the aggregation kinetics and minimize the effect of any artifact related to a particular assay. Based on their results, Necula et al. categorized their screens into three classes: class I consisted of compounds that inhibited oligomerization but not fibrillization, class II consisted of compounds that inhibited both oligomerization and fibrillization and class III were compounds that inhibited fibrillization and not oligomerization ( Table 7) . 42 The data suggest that it may be possible to selectively inhibit "off-pathway" intermediates and/or fibril formation. This study agrees quite well with a screen of small molecules against tau filament formation and Aβ 1-40 aggregation reported by Taniguchi et al. 130 A comparison of the IC 50 values reported by the two groups showed very similar trends in inhibitory activity and thus provides the field with a useful set of standard molecules ( Figure 6 ). Interestingly, the A11 antibody is crossreactive with a wide variety of oligomeric species, 118 indicating that inhibitors may have general applicability across many different aggregation diseases.
A clever approach combines small molecule targeting with natural bystander proteins to prevent amyloid aggregation. 150 Gestwicki et al. designed a bifunctional molecule by covalently tethering a synthetic ligand (SLF) to Congo red (CR) (Figure 7 a) . 150 CR at one end interacts with aggregated Aβ whereas the synthetic ligand recruits a molecular chaperone (FKBP), providing the small molecule derivative with the necessary steric bulk to disrupt Aβ aggregation. This approach significantly enhanced the potency of CR by several-fold (IC 50 of CR, 2.9 μM; IC 50 SLF-CR/FKBP, 0.52 μM). SLF-CR/FKBP Table 6 . Hydroxyaniline derivatives inhibited Aβ oligomerization in APP-expressing CHO cells. 144 6-ethyl-N,N′-bis(3-hydroxyphenyl) [1, 3, 5] triazine-2,4-diamine N′-bis (3-hydroxyphenyl) pyridazine-3,6-diamine (RS-0466) (RS-0406)
Comparison of results for RS-0466 and RS-0406
Nakagami et al. 145 Walsh et al. 144 
RS-0466 did not affect Aβ fibrillization when measured by ThT
These results were reproduced by Walsh et al. in their in vitro assay, RS-0406 inhibited fibrillization, and also disassembled studies. preformed Aβ fibrils.
RS-0466 and RS-0406 inhibited Aβ induced cytotoxicity in HeLa
Both compounds prevented formation of Aβ oligomers in cells and blocked impairment of long-term potentiation in rat living cells (7A2 cells) and blocked Aβ-mediated LTP. hippocampal slices.
How these compounds inhibited Aβ induced cytotoxicity was not
It was shown that RS-0466 and RS-0406 inhibited the formation studied.
of new oligomers, they did not affect preformed Aβ oligomers. treated neurons displayed normal morphology and high cell viability (~70 %). To further increase the potency of the bivalent inhibitor, the authors varied the linker length between SLF and CR. Of the three new molecules created (Figure 7 b) , SLFBenz-CR/FKBP was most effective with an IC 50 of 50 nM. The authors did observe the presence of small aggregates in electrophoretic analysis and AFM images in Aβ samples treated with their bifunctional molecule. Finally a screen has been developed for the discovery of Aβ aggregation inhibitors in E. coli cells. 151 This approach takes advantage of a green fluorescent protein (GFP) based assay 152 where the fluorescence of GFP is compromised by attachment of Aβ, presumably due to GFP-misfolding mediated by Aβ aggregation. GFP folding and fluorescence is recovered upon treatment of the E. coli with small molecules that likely disrupt Aβ aggregation. This may be a useful approach for the rapid screening of small molecule Aβ inhibitors and could eventually be used in more permeable mammalian cells.
Overall, the small molecule approach to Aβ aggregation inhibition is clearly poised to provide new and useful reagents for in vivo diagnostics as therapeutic applications are already being demonstrated for analogues of classic Aβ binders such as Congo Red and ThT. The existing small molecules are also being probed for their ability to interact with different amyloid species along the fibrillization pathway, which when correlated with cellular toxicity studies will likely provide useful protocols for evaluating new anti-Aβ molecules as they are identified. 130 and Necula et al. 42 for the inhibition of Aβ aggregation by small molecules. 
Summary
In this review we have aimed to provide a comprehensive view of the rapidly growing molecular toolbox at our disposal for targeting Aβ. We have described a wide range of molecules that target Aβ, including natural proteins, peptides, peptidomimetics, and small molecules. We have also described recent approaches for selections and screens for developing Aβ targeting antibodies, proteins, and peptides that have been shown to interact with Aβ oligomers and fibrils and influence aggregation kinetics. These new strategies and the resulting molecules being discovered provide a starting point for analogue synthesis that should help in furthering our understanding of the mechanism of Aβ aggregation and ultimately aid in reducing cellular toxicity. Moreover, many of these new approaches may be applied to other amyloidogenic diseases. These molecules provide new and interesting design opportunities as seen in the case of the novel small molecule directed chaperones. Opportunities clearly exist for utilizing the described small molecules and peptides discovered to date for decorating discrete multivalent dendrimers to provide new multivalent entities for targeting both oligomers and fibrils. 93, 153, 154 Thus with this growing toolbox in hand, new methods for the molecular design of diagnostic and therapeutic agents will clearly be forthcoming.
Outlook
The study of the aggregation pathway of Aβ is a difficult and challenging endeavor and future work in targeting Aβ will necessitate the development of sensitive analytical methods that continue to clarify molecular mechanisms for the pathophysiology of Alzheimer's disease. Furthermore, new biophysical studies must aim to correlate in vivo toxicity with in vitro aggregation models to allow for accurate interpretation of the mechanism of action of the molecules that are currently available. From a molecular design perspective, the many ligands that we have described should be amenable to further chemical functionalization with appropriate imaging agents to develop new and powerful in vitro and in vivo assays that target different species in the fibrillization pathway. This approach will allow for the development of molecules that target specific Aβ assemblies and correlate them to disease outcomes. As an example, many of the reported small molecules that target oligomers and fibrils, will likely be amenable to radioisotope incorporation for in vivo diagnostic imaging with PET (Positron Emission Tomography) 155 and SPECT (Single Photon Emission Computerized Tomography). 139, 156 Thus at the current time we are clearly at the threshold of discovering new diagnostic tools as well as therapeutic molecules that may help ameliorate the devastating neurological effects of Alzheimer's disease.
